Citicoline May Prevent Cognitive Decline in Patients with Cerebrovascular Disease

References

• Alvarez-Sabín J, Román GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013;3(3):1395–1414. doi:10.3390/brainsci3031395
   PubMedGoogle Scholar
• Barker Collo S, Feigin VL, Parag V, Lawes CM, Senior H. Auckland stroke outcomes study. Part 2: cognition and functional outcomes 5 years poststroke. Neurology. 2010;75(18):1608–1616. doi:10.1212/WNL.0b013e3181fb44c8
   PubMed Web of Science ®Google Scholar
• Alvarez Sabín J, Román GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42(Suppl. S1):S40–S43. doi:10.1161/STROKEAHA.110.606509
   PubMedGoogle Scholar
• Ganguli M, Fu B, Snitz BE, et al. Vascular risk factors and cognitive decline in a population sample. Alzheimer Dis Assoc Disord. 2014;28(1):9–15. doi:10.1097/WAD.0000000000000004
   PubMed Web of Science ®Google Scholar
• Benedictus MR, Van Harten AC, Leeuwis AE, et al. White matter hyperintensities relate to clinical progression in subjective cognitive decline. Stroke. 2015;46(9):2661–2664. doi:10.1161/STROKEAHA.115.009475
   PubMed Web of Science ®Google Scholar
• Royall DR, Lauterbach EC, Kaufer D, Malloy P, Coburn KL, Black KJ. The cognitive correlates of functional status: a review from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatr Clin Neurosci. 2007;19(3):249–265. doi:10.1176/jnp.2007.19.3.249
   PubMed Web of Science ®Google Scholar
• Gaugler JE, Kane RL, Kane RA, Clay T, Newcomer R. Caregiving and institutionalization of cognitively impaired older people: utilizing dynamic predictors of change. Gerontologist. 2003;43(2):219–229. doi:10.1093/geront/43.2.219
   PubMed Web of Science ®Google Scholar
• Fernández-Blázquez MA, Ávila-Villanueva M, Maestú F, Medina M. Specific features of subjective cognitive decline predict faster conversion to mild cognitive impairment. J Alzheimer’s Dis. 2016;52(1):271–281. doi:10.3233/JAD-150956
   PubMed Web of Science ®Google Scholar
• Craig L, Hoo ZL, Yan TZ, Wardlaw J, Quinn TJ. Prevalence of dementia in ischemic or mixed stroke populations: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93(2):180–187. doi:10.1136/jnnp-2020-325796
   PubMedGoogle Scholar
• Unverzagt FW, McClure LA, Wadley VG, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology. 2011;77(19):1729–1736. doi:10.1212/WNL.0b013e318236ef23
   PubMed Web of Science ®Google Scholar
• Seshadri S, Wolf PA, Beiser A, et al. Stroke risk profile, brain volume, and cognitive function. The Framingham Offspring Study. Neurology. 2004;63(9):1591–1599. doi:10.1212/01.WNL.0000142968.22691.70
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Scuteri A, Black SE, et al. AHA/ASA Scientific statement: vascular contributions to cognitive impairment and dementia. Stroke. 2011;42(9):2672–2713. doi:10.1161/STR.0b013e3182299496
   PubMed Web of Science ®Google Scholar
• Haan MN, Shemanski L, Jagust WJ, Manolino TA, Kuller L. The role of APOE E4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282(1):40–46. doi:10.1001/jama.282.1.40
   PubMed Web of Science ®Google Scholar
• Gareri P, Castagna A, Cotroneo AM, et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages and doubts for an old drug with new perspectives. Clin Interv Aging. 2015;10:1421–1429. doi:10.2147/CIA.S87886
   PubMed Web of Science ®Google Scholar
• Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(Suppl 5):S1–S89. doi:10.33588/rn.75s05.2022311
   PubMedGoogle Scholar
• Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002;17(4):314–321. doi:10.1097/00001199-200208000-00005
   PubMed Web of Science ®Google Scholar
• Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011;42(Suppl 1):S33–S35. doi:10.1161/STROKEAHA.110.597435
   PubMed Web of Science ®Google Scholar
• Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014;28(3):185–193. doi:10.1007/s40263-014-0144-8
   PubMed Web of Science ®Google Scholar
• Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernández M, Díez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299(1–2):188–192. doi:10.1016/j.jns.2010.08.027
   PubMed Web of Science ®Google Scholar
• Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131. doi:10.2147/CIA.S38420
   PubMed Web of Science ®Google Scholar
• Gareri P, Castagna A. Citicoline in vascular cognitive impairment. Some latest evidences. Ann Alzheimers Dement Care. 2017;2(1):18–19. doi:10.17352/aadc.000004
   Google Scholar
• Alvarez-Sabin J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146–154. doi:10.1159/000346602
   PubMed Web of Science ®Google Scholar
• Alvarez-Sabin J, Santamarina E, Maisterra O, et al. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. Int J Mol Sci. 2016;17(3):390. doi:10.3390/ijms17030390
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Dorado R, Zea-Sevilla MA. Role of citicoline in patients with mild cognitive impairment. Neurosci Insights. 2023;18:26331055231152496. doi:10.1177/26331055231152496
   Google Scholar
• Sikaroodi H, Yadegari S, Miri SR. Cognitive impairments in patients with cerebrovascular risk factors: a comparison of Mini Mental Status Exam and Montreal Cognitive Assessment. Clin Neurol Neurosurg. 2013;115(8):1276–1280. doi:10.1016/j.clineuro.2012.11.026
   PubMed Web of Science ®Google Scholar
• Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, et al. Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimers Res Ther. 2018;10(1):123. doi:10.1186/s13195-018-0449-9
   PubMed Web of Science ®Google Scholar
• Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985–1992. doi:10.1001/archneur.58.12.1985
   PubMed Web of Science ®Google Scholar
• Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology. 2012;79(15):1591–1598. doi:10.1212/WNL.0b013e31826e26b7
   PubMed Web of Science ®Google Scholar